Literature DB >> 11753084

Bone morphogenetic protein-7: an anti-fibrotic morphogenetic protein with therapeutic importance in renal disease.

Richard J Lund1, Matthew R Davies, Keith A Hruska.   

Abstract

Bone morphogenetic proteins are members of the transforming growth factor-beta superfamily of cytokines and consist of a group of at least 15 morphogens involved in intracellular messaging through complex bone morphogenetic protein receptor mediated Smad signaling. Bone morphogenetic protein-7 knockout mice die shortly after birth due to uremia, demonstrating that this morphogenetic protein is essential for renal development. Recent investigations have characterized renal bone morphogenetic protein-7 receptors, shown exogenous bone morphogenetic protein-7 to prevent fibrogenesis associated with ureteral obstruction, indicated a loss of renal bone morphogenetic protein-7 associated with diabetic nephropathy, and an improvement in glomerular pathology in rodent streptozocin-induced diabetes with bone morphogenetic protein-7 treatment. In addition, this morphogenetic protein has been shown to reduce glomerulonephritis and tubulointerstitial fibrosis in a murine model of lupus nephritis as well as decrease the peritrabecular fibrosis associated with murine high turnover renal osteodystrophy. Finally, we review the effects of bone morphogenetic protein-7 on vascular calcification in an animal model, a potential complication of this therapy given its osseous morphogenetic effect.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11753084     DOI: 10.1097/00041552-200201000-00005

Source DB:  PubMed          Journal:  Curr Opin Nephrol Hypertens        ISSN: 1062-4821            Impact factor:   2.894


  7 in total

Review 1.  Arterial stiffness, vascular calcification and bone metabolism in chronic kidney disease.

Authors:  János Nemcsik; István Kiss; András Tislér
Journal:  World J Nephrol       Date:  2012-02-06

2.  Uterine sensitization-associated gene-1 (USAG-1), a novel BMP antagonist expressed in the kidney, accelerates tubular injury.

Authors:  Motoko Yanagita; Tomohiko Okuda; Shuichiro Endo; Mari Tanaka; Katsu Takahashi; Fumihiro Sugiyama; Satoshi Kunita; Satoru Takahashi; Atsushi Fukatsu; Masashi Yanagisawa; Toru Kita; Takeshi Sakurai
Journal:  J Clin Invest       Date:  2005-12-08       Impact factor: 14.808

3.  IHG-1 amplifies TGF-beta1 signaling and is increased in renal fibrosis.

Authors:  Madeline Murphy; Neil G Docherty; Brenda Griffin; Jillian Howlin; Emmett McArdle; Ruth McMahon; Holger Schmid; Matthias Kretzler; Alejandra Droguett; Sergio Mezzano; Hugh R Brady; Fiona Furlong; Catherine Godson; Finian Martin
Journal:  J Am Soc Nephrol       Date:  2008-05-28       Impact factor: 10.121

4.  Pretreatment with bone morphogenetic protein-7 (BMP-7) mimics ischemia preconditioning following intestinal ischemia/reperfusion injury in the intestine and liver.

Authors:  Ravi S Radhakrishnan; Geetha L Radhakrishnan; Hari R Radhakrishnan; Hasen Xue; Sasha D Adams; Stacey D Moore-Olufemi; Matthew T Harting; Charles S Cox; Bruce C Kone
Journal:  Shock       Date:  2008-11       Impact factor: 3.454

Review 5.  Regression of vascular calcification in chronic kidney disease - feasible or fantasy? a review of the clinical evidence.

Authors:  Oscar Leonard; Jonas Spaak; David Goldsmith
Journal:  Br J Clin Pharmacol       Date:  2013-10       Impact factor: 4.335

6.  Lung remodeling in a mouse model of asthma involves a balance between TGF-β1 and BMP-7.

Authors:  Camila Leindecker Stumm; Erik Halcsik; Richardt Gama Landgraf; Niels Olsen Saraiva Camara; Mari Cleide Sogayar; Sonia Jancar
Journal:  PLoS One       Date:  2014-04-29       Impact factor: 3.240

Review 7.  The role of bone morphogenetic protein signaling in vascular calcification.

Authors:  Peiran Yang; Luca Troncone; Zachary M Augur; Stephanie S J Kim; Megan E McNeil; Paul B Yu
Journal:  Bone       Date:  2020-07-28       Impact factor: 4.398

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.